Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.

@article{Yu2011OncedailyDE,
  title={Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.},
  author={Evan Y Yu and Christophe Massard and Mitchell E Gross and Michael Anthony Carducci and St{\'e}phane Culine and Gary Hudes and Edwin M Posadas and Cora N Sternberg and George Wilding and G{\'e}ralyn C. Trudel and Prashni Paliwal and Karim S Fizazi},
  journal={Urology},
  year={2011},
  volume={77 5},
  pages={
          1166-71
        }
}
OBJECTIVES To determine the activity and tolerability of 100-mg once-daily (QD) dasatinib in patients with metastatic castration-resistance prostate cancer (CRPC). Dasatinib, an oral Src family kinase inhibitor, has demonstrated both preclinical and clinical activity with twice-daily dosing in patients with metastatic CRPC. METHODS Chemotherapy-naive men with metastatic CRPC and increasing prostate-specific antigen levels were treated with dasatinib 100 mg QD. The primary measurement was a… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 48 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration - resistant prostate cancer

LJ Lombardo, FY Lee, P Chen
  • J Clin Oncol
  • 2010

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

Theodore D. Koreckij, Holly M. Nguyen, +3 authors Eva Corey
  • British Journal of Cancer
  • 2009

Phase II study of dasatinib in patients with metastatic castration - resistant prostate cancer

NP Shah, HM Kantarjian, DW Kim
  • Clin Cancer Res
  • 2009

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 2 EXCERPTS

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2008